Table 4.

Unadjusted and adjusted ratio of prescribed dose of ESA in HD patients compared to PD patients across hemoglobin levels using multivariate Poisson regression models

Hemoglobin	Unadjusted	Hemoglobinadjusted	Case-mixadjusted	Case-mix- and MICS-adjusted
<9.0 g/dl	4.1 (3.6–4.8)	4.2 (3.6–4.8)	4.3 (3.7–4.9)	4.4 (3.8–5.1)
9.0 to <9.5 g/dl	4.6 (3.9–5.5)	4.6 (3.9–5.5)	4.8 (4.0–5.8)	5.0 (4.1–6.0)
9.5 to <10.0 g/dl	3.1 (1.9–4.9)	3.1 (1.9–4.9)	3.0 (1.9–4.9)	3.1 (1.9–4.9)
10.0 to <10.5 g/dl	3.8 (3.3–4.3)	3.8 (3.3–4.3)	3.8 (3.3–4.4)	3.8 (3.3–4.4)
10.5 to <11.0 g/dl	3.8 (3.6–4.1)	3.8 (3.6–4.2)	4.0 (3.7–4.3)	4.0 (3.7–4.3)
11.0 to <11.5 g/dl	3.6 (3.4–3.9)	3.6 (3.4–3.9)	3.8 (3.5–4.0)	3.7 (3.5–4.0)
11.5 to <12.0 g/dl	3.2 (3.1–3.4)	3.3 (3.1–3.5)	3.4 (3.2–3.7)	3.4 (3.2–3.7)
12.0 to <12.5 g/dl	3.5 (3.3–3.7)	3.5 (3.3–3.7)	3.7 (3.5–4.0)	3.7 (3.5–3.9)
12.5 to <13.0 g/dl	3.6 (3.4–3.8)	3.6 (3.4–3.8)	3.7 (3.5–3.9)	3.7 (3.5–4.0)
13.0 to <13.5 g/dl	3.4 (3.2–3.7)	3.4 (3.2–3.7)	3.5 (3.3–3.8)	3.5 (3.3–3.8)
13.5 to <14.0 g/dl	3.4 (3.1–3.8)	3.4 (3.1–3.8)	3.5 (3.1–3.84)	3.5 (3.1–3.9)
≥14 g/dl	3.2 (3.0–3.5)	3.2 (3.0–3.5)	3.2 (3.0–3.4)	3.1 (2.9–3.3)

ESA doses are averaged over the entire calendar quarter (13 weeks) per patient. Data are from 10,527 PD patients and 139,103 HD patients between 7/2001 and 6/2006.